Olaparib for PAH: a Multicenter Clinical Trial
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
WIRE - Novel Treatments in Renal Cell Cancer
- Status
- RECRUITING
- Phase
- PHASE2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- Status
- COMPLETED
- Phase
- PHASE3
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
- Status
- UNKNOWN
- Phase
- PHASE2
Study to Evaluate CCS1477 in Advanced Tumours
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2